Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis

Bone marrow tissue supports the complex microenvironment for numerous cell types and bone marrow aspirate can be used whole, concentrated, or as a source for stem cells [19]. BM-MSCs can be isolated from aspirate and have gained significant attention in the regenerative medicine field [22] due to their multilineage differentiation potential, immunomodulatory and self-renewal capacities [21, 23].

BM-MSCs promote repair via paracrine signalling mechanisms and the secretion of soluble trophic factors including bone morphogenetic protein-2 (BMP2) and insulin-like growth factor-1 (IGF1) [24]. These factors enhance cellular regeneration and induce bone formation by stimulating proliferation and differentiation of endogenous semi-like progenitors found in most tissues and by decreasing OA inflammatory and immune reactions [25]. BM-MSCs also inhibit T- and B-lymphocyte activation by inhibiting inflammatory cytokine production, thereby preventing immune responses and consequently promoting immune tolerance. Furthermore, BM-MSCs stimulate anti-inflammatory interleukin-1 (IL-1) supporting the generation of anti-inflammatory T-cells [26]. To guarantee these characteristics and standardise MSC classification, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) has defined MSC criteria (Table 2) to improve the validity and consistency of research trials.

Pre-clinical studies investigating BM-MSCs for cartilage repair in animal models have demonstrated encouraging results (Table 3) [27‐33]; subsequently, clinical applications are increasing (Table 4) [30, 34‐44]. BM-MSCs administered for KOA in clinical patients adhere to damaged tissue surfaces, and differentiate into chondrocytes, resulting in anatomic restoration with significant improvements regarding pain and function [40, 43]. However, some studies have challenged whether BM-MSCs treatments are applicable to all OA grades [45‐47]. Across research studies, a variety of outcome measures have been utilised, with some studies reliant upon qualitative questionnaires including The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Lequesne algofunctional indexes [20] to evaluate success, which may introduce unintended bias [38, 42], due to physicians influencing patient responses. This may be improved by digital administration of questionnaires therefore, it will be completed individually with no external input [48].

Within the literature reviewed, the follow-up periods and outcome criteria varied. Periods up to 12-month post-injection have been followed, with clinical outcomes including increased cartilage thickness, function and pain measured [34]. Despite reported improvements, not all are significant. Contrastingly, greater BM-MSC longevity with significant changes in both qualitative and quantitative after-effects have been reported [34, 44, 49]. An injection of 40 × 10⁶ cells in 12 patients with advanced KOA displayed significant improvements in VAS and quality of articular cartilage without diminution between a 12 [40] and 24-month follow-up [44]. Davatchi et al. [37] reported a 5-year follow-up post injection of 8–9 × 10⁶ BM-MSCs in 4 patients and observed progressive deterioration, although outcomes were improved compared to baseline measurements, suggesting a protective role of BM-MSCs compared to untreated controls. Despite prolonged follow-up periods, limited patient numbers and lack of in-depth statistical analysis make it difficult to draw robust conclusions regarding the overall therapeutic efficacy [50].

Compared to autologous BM-MSCs, allogenic BM-MSCs represent an alternative cell source. Multiple randomised control trials (RCTs) have reported improved outcomes with various doses (25 × 10⁶–50 × 10⁶ cells), which are safe and well tolerated, whereas higher doses can produce adverse events [30]. Despite positive trends in similar studies [43, 44], few clinical parameters were significantly improved; with no critical changes in X-ray and Magnetic Resonance Imaging (MRI) compared to baseline measurements. Although BM-MSCs are considered poorly immunogenic, allogenic cells may stimulate immune responses and thus, the identification of an optimum dose is crucial for viable treatment strategies [50].

There is currently limited evidence for simultaneous improved clinical outcomes, including pain, function, and cartilage repair. However, improvements following the application of intra-articular BM-MSCs at short-term follow-up have been reported [22]. Several studies have reported improved cartilage thickness; however, meaningful changes in clinical outcomes are sporadic. Moreover, studies using both autologous and allogenic BM-MSCs have been explored within the literature, including co-administered and ex-vivo expanded treatments [30, 49].

Autologous BM-MSC injections are the dominant cell choice in clinical studies reported for treating KOA [51]. In an early case report [35], a single patient was injected with 22.4 × 10⁶ cells suspended in phosphate-buffered saline (PBS) with a dexamethasone post-injection as a differentiating agent [52]. The 3-month follow-up reported no adverse events, with significantly increased cartilage and meniscus growth, with minor improvements in range of motion (ROM) and pain scores. This was the first report of increased meniscus size in humans; however, the methodology lacked specificity and a detailed exploration of the dexamethasone effects was not conveyed [52]. MRI revealed significant cartilage thickening covering the distal femur and proximal tibia at 6 and 12 months, yet symptomatic and functional improvements were not apparent. This study failed to acknowledge potential author or methodological bias and so further pilot and clinical studies are required to replicate meaningful findings.

Davatchi et al. [36] emphasised the safety of BM-MSC injections, claiming marked improvements in (qualitative) outcome parameters, with physical parameters improving to a lesser extent. In comparison to Centeno et al. [35], a lower dosage of 8–9 × 10⁶ BM-MSCs were administered, potentially accounting for lower physical parameter improvements. The follow-up from a 2011 case series [37] argued that the lack of significant outcomes is due to all participants having advanced-stage OA.

Emadedin et al. [38] performed a similar study on a small patient cohort (n = 6), using 20–24 × 10⁶ cells, reporting significant improvements in pain and function (WOMAC) at both 6 and 12 months. A long-term follow-up of the same cohort affirmed previous findings, revealing that BM-MSC dosages were safe and therapeutically beneficial. Nevertheless, between 12 and 30 months, therapeutic improvements declined in all individuals, suggesting the need for subsequent administration for prolonged benefit [39].

Despite reported therapeutic benefits of BM-MSCs, the generalisability of the results and techniques used for larger populations with symptomatic KOA is limited. This highlights the requirement for larger, blinded RCTs to improve study comparability and clinical validity. Likewise, within study designs, sample size calculations should be utilised for methodological and ethical reasons. Otherwise, reported findings should be interpreted with caution, as smaller samples may undermine internal and external study validity.

A clinical RCT (phase I/II) of 30 patients with grade ≥ 2 OA used a sample size calculation that provided an effect size of 0.6 and, a power of 80% [49]. Group randomisation was performed, potentially facilitating the increased cohort size compared to previous studies (n = 30), whilst reducing bias [53]. Despite randomisation, the stage of OA was more severe in those receiving low-dose BM-MSCs (10 × 10⁶), which may have prevented these patients achieving more positive outcomes [49]. The study included blinded radiologists to reduce bias (extra KOA MRIs were randomly added during analysis). Ethical issues prevented double-blinding; thus, qualitative clinical scores were compared with objective measures to minimise bias. A control, low-dose and high-dose group were followed for 12 months. Outcomes were significant at 3, 6 and 12 months and correlations revealed a significant reduction in low-and-high-dose VAS scores at all time points, which correlated with improved ROM compared to the control group. Importantly, this study co-administered hyaluronic acid (HA) and indicated that a single injection is a safe and feasible procedure, resulting in both clinical and functional improvements; particularly when 100 × 10⁶ cells were administered.

Additional studies using allogenic BM-MSCs also used HA either as a control group or as a cell suspension [43, 44]. However, cells from young, healthy donors may not reflect growth and differentiation characteristics of MSCs from elderly and/or OA patients [54]. Yet, they equally showed improvements in pain and function. Espinosa et al. [55] described a decrease in knee joint space in control groups (HA) at 12 months. Whereas Vangsness et al. and Vega et al. [43, 44] provided MRI analysis using T2 mapping of cartilage and, computational analysis of meniscus volume to assess the effects of BM-MSCs more closely. Vega et al. [44] found significant decreases in poor cartilage index (PCI) at 12-month following injection of 40 × 10⁶ cells. Conversely, a dosage of 50 × 10⁶ cells [43] identified significantly increased meniscus volume (> 15%) at 12 months, which continued 2 years post-injection. Orozco et al. [40] also reported significant improvements in PCI following treatment with autologous BM-MSCs with continued improvement over the 2-year follow-up. A significant correlation between VAS and PCI was reported, demonstrating that both cartilage and pain/function improvements occur simultaneously. This study supersedes previous case reports where results were described as “satisfactory” [39], as cell dosages were larger, the follow-up was longer and the MRI investigation provided robust quantitative analysis.

Alternative methodologies for the application of MSCs into KOA patients exist, however these are more invasive but do allow more specific targeting of focal cartilage defects. Brittberg et al. and Bornes et al. have both comprehensively discussed the use of MSCs (not just limited to BM-MSCs) in the specific treatment of cartilage defects considering multiple therapy options [56, 57].

The feasibility and safety of both allogenic and autologous cells have been reiterated throughout literature [40, 41]; yet, studies utilising higher doses regularly report increased adverse events. In a sample of 55 patients, 247 adverse events were reported, with one life-threatening, 1-year post-injection when using allogenic BM-MSCs [43]. Minor adverse events, such as post-implantation pain and inflammation, occur with similar frequencies (50%) between studies using autologous BM-MSCs [40, 49]. Most adverse events were resolved within 24–48 h following treatment with pain medication. Nevertheless, adverse events were not reported in every study [35, 39, 41].

Close attention to adverse events may be key to clinical translation when optimising BM-MSCs as a KOA therapy [51]. The majority of literature reports use of either autologous or allogenic BM-MSCs, however studies have also included infused BM-MSCS [30, 42]. Soler et al. [42] produced an analysis of a prospective, open-label, single-arm clinical trial for the infusion of XCEL-M-Alpha into autologous BM-MSCs. Significant improvements in VAS, WOMAC and Lequesne algofunctional index were observed following a 40 × 10⁶ injection. However, this is one of the first to infuse BM-MSCs and the omission of control groups makes it difficult to evaluate efficacy. The indistinct method regarding infusion is inconsistent with the detailed explanation of cell isolation and expansion and therefore, the methodology may be lacking suitable description. Furthermore, Gupta et al. [30] injected ex vivo expanded, pooled allogenic BM-MSCs (Stempeucel^®) into 60 patients who were split into four different dosage groups (with a control each) in a randomised, double-blinded multicentre placebo-controlled study (RCT). However, unblinding of the trial occurred after 6-month follow-up even though subjective measurements were continuously analysed; after this point, results should be interpreted with circumspection. The therapeutic effect of BM-MSCs was not explored without HA, but both pre-clinical and clinical studies suggest that BM-MSCs co-administered with HA tends to produce greater regenerative benefit [58]. This study also failed to produce any significant outcomes, which was potentially due to the procedure employed with higher dosages and volumes (75 and 150 million cells) being restricted in the limited joint space; possibly causing cell aggregation. The study may have been more valuable if lower dosages were also examined.

Overall, there is moderate-to-high level evidence of safety to recommend therapeutic administration of BM-MSCs for KOA, for both animal and human studies; suggesting therapeutic benefit. Several published results, especially conclusions and speculations drawn from case/preliminary reports, do not have the weight of findings compared to RCTs. Therefore, when interpreting results, due diligence is recommended. Furthermore, the significance of experimental outcomes may be influenced by the prevalent study heterogeneity including: the use of a variety of cell doses and donors; variability in functionality and pain scores; severity of KOA; various cell processing methods and differing follow-up periods [59].

Due to the immune-privileged status of MSCs [60], allogenic BM-MSCs show more promise compared to autologous, since they allow manufacturing of large batches or ‘off-the-shelf’ products in the future [61]. This would enhance the reliability of production whilst decreasing the costs of cell therapies [62], however, long-term efficacy data are warranted.

Conflicting study results may result from methodological heterogeneity or, the limitation of BM-MSCs remaining localised within the tissue. This may be caused by the rapid cycling of synovial fluid or due to large volumes injected into the knee causing cell apoptosis. Despite reported adverse events, the outcomes across the published studies are influential in demonstrating that the benefits may outweigh the treatment risks. Despite BM-MSCs intra-articular injections potentially having a limited therapeutic effect on cartilage volume [51], the clinical and functional outcomes are favourable in patients with chronic KOA. In terms of evaluating BM-MSC efficacy, it may be more applicable for future studies to only focus on long-term, large-scale RCTs as non-RCTs tend to have greater bias and more confounders, affecting the interpretation and validity of efficacy [22]. Future studies need to determine the type and quality of the repaired cartilage tissues, its durability and the association between objective and subjective outcome improvements [22].